XT

Xtant Medical Holdings IncNYSE-MKT XTNT Stock Report

Last reporting period 30 Jun, 2024

Updated 12 Nov, 2024

Last price

Market cap $B

0.094

Micro

Exchange

XASE - Nyse MKT LLC

XTNT Stock Analysis

XT

Uncovered

Xtant Medical Holdings Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-8/100

Low score

Market cap $B

0.094

Dividend yield

Shares outstanding

108.9 B

Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 134 full-time employees. The company went IPO on 2010-06-30. The firm is focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. Its products are used by orthopedic spine surgeons and neurosurgeons to treat a variety of spinal disorders in the cervical, thoracolumbar, and interbody spine. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, and its line of 3Demin products, as well as other allografts. The company offers a comprehensive line of products that are used to treat a variety of spinal and sacroiliac conditions, including trauma, degeneration, deformity and tumor. The Company’s key spinal implant product lines include Cervical Products, Thoracolumbar Products, Interbody Products, and Interlaminar Stabilization Products.

View Section: Eyestock Rating